Analytical Data
-
Gene name
CCNB2
- Application
-
Alternative Names
CCN-B2; G2/mitotic-specific cyclin-B2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95067
-
Expression Region
Val58~Ser398
-
Molecular Weight
43kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCNB2, or Cyclin B2, is a crucial regulatory protein involved in the control of the cell cycle, particularly during the transition from the G2 phase to mitosis. As a member of the cyclin family, CCNB2 partners with cyclin-dependent kinases (CDKs), specifically CDK1, to form a complex that drives the phosphorylation of target proteins, thereby promoting the progression of cell division. Research has shown that aberrations in CCNB2 expression and activity are associated with various cancers, suggesting its potential role as a biomarker for tumorigenesis and disease progression. The need for CCNB2-derived recombinant proteins arises from their potential applications in understanding cell cycle dynamics and developing targeted therapies. The production of these proteins enables detailed studies into their structure-function relationships, interactions with other cell-cycle regulators, and contributions to oncogenic processes. Furthermore, recombinant CCNB2 can facilitate high-throughput screening of novel compounds that may modulate its activity, paving the way for therapeutic innovations in cancer treatment. In recent years, advancements in protein engineering and expression systems have enhanced the yield and functionality of recombinant CCNB2, making it a valuable tool for both basic and applied research in oncology. The ongoing investigations into CCNB2's roles necessitate a comprehensive understanding of its biochemical properties and interactions, underscoring the importance of topical research involving its recombinant forms. Thus, the exploration of recombinant CCNB2 not only enriches our comprehension of cell cycle regulation but also offers promising avenues for clinical applications in cancer therapy.
